Stephen Dale - Jan 27, 2023 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Medical Officer
Signature
Teresa Bair, Attorney-in-fact for Stephen Dale
Stock symbol
KURA
Transactions as of
Jan 27, 2023
Transactions value $
-$128,033
Form type
4
Date filed
1/31/2023, 04:10 PM
Previous filing
Jan 28, 2022
Next filing
Feb 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Sale -$60.9K -4.39K -11.88% $13.89 32.5K Jan 27, 2023 Direct F1
transaction KURA Common Stock Sale -$67.1K -4.84K -14.89% $13.87 27.7K Jan 27, 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.
F2 This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022.
F3 This transaction was executed in multiple trades at prices ranging from $13.62 to $14.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.